Evidence map›Paper›PMID 34523110›Full record

ArticleInternational journal of hematology2021

Pharmacokinetically guided, once-daily intravenous busulfan in combination with fludarabine for elderly AML/MDS patients as a conditioning regimen for allogeneic stem cell transplantation.

Chikako Ohwada, Shingo Yamazaki, Katsuhiro Shono, Kensuke Kayamori, Yutaro Hino, Nagisa Oshima-Hasegawa, Tomoya Muto, Shokichi Tsukamoto, Shio Mitsukawa, Yusuke Takeda and 9 more

Abstract read
PubMed Publisher
In one paragraph

Article in International journal of hematology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.4field-weighted citation impact, top 36% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 3 citations in OpenAlex.

  1. Review
  2. Observational
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors at 3 institutions in 1 country.

Chikako OhwadaDepartment of Hematology, Chiba University Hospital, 1-8-1 Inohana, Chuo-ku, Chiba, 260-8670, Japan. cohwada@iuhw.ac.jp.ORCID http://orcid.org/0000-0001-9648-940X
Shingo YamazakiDivision of Pharmacy, Chiba University Hospital, Chiba, Japan.
Katsuhiro ShonoDepartment of Hematology, Aoba Municipal Hospital, Chiba, Japan.
Kensuke KayamoriDepartment of Hematology, Chiba University Hospital, 1-8-1 Inohana, Chuo-ku, Chiba, 260-8670, Japan.
Yutaro HinoDepartment of Hematology, Chiba University Hospital, 1-8-1 Inohana, Chuo-ku, Chiba, 260-8670, Japan.
Nagisa Oshima-HasegawaDepartment of Hematology, Chiba University Hospital, 1-8-1 Inohana, Chuo-ku, Chiba, 260-8670, Japan.
Tomoya MutoDepartment of Hematology, Chiba University Hospital, 1-8-1 Inohana, Chuo-ku, Chiba, 260-8670, Japan.
Shokichi TsukamotoDepartment of Hematology, Chiba University Hospital, 1-8-1 Inohana, Chuo-ku, Chiba, 260-8670, Japan.
Shio MitsukawaDepartment of Hematology, Chiba University Hospital, 1-8-1 Inohana, Chuo-ku, Chiba, 260-8670, Japan.
Yusuke TakedaDepartment of Hematology, Chiba University Hospital, 1-8-1 Inohana, Chuo-ku, Chiba, 260-8670, Japan.
Naoya MimuraDepartment of Hematology, Chiba University Hospital, 1-8-1 Inohana, Chuo-ku, Chiba, 260-8670, Japan.
Masahiro TakeuchiDivision of Hematology-Oncology, Chiba Cancer Center, Chiba, Japan.
Tohru IsekiDepartment of Hematology, Chiba University Hospital, 1-8-1 Inohana, Chuo-ku, Chiba, 260-8670, Japan.
Masahiro OnodaDepartment of Hematology, Aoba Municipal Hospital, Chiba, Japan.
Akira YokotaDepartment of Hematology, Aoba Municipal Hospital, Chiba, Japan.
Takaaki SuzukiDivision of Pharmacy, Chiba University Hospital, Chiba, Japan.
Itsuko IshiiDivision of Pharmacy, Chiba University Hospital, Chiba, Japan.
Chiaki NakasekoDepartment of Hematology, Chiba University Hospital, 1-8-1 Inohana, Chuo-ku, Chiba, 260-8670, Japan.
Emiko SakaidaDepartment of Hematology, Chiba University Hospital, 1-8-1 Inohana, Chuo-ku, Chiba, 260-8670, Japan.
Chiba University Hospital · JPChiba Aoba Municipal Hospital · JPChiba Cancer Center · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The efficacy of pharmacokinetically (PK) guided, once-daily administration of busulfan (BU) was evaluated in elderly patients with acute myeloid leukemia/myelodysplastic syndrome (AML/MDS). Twenty-one patients (median age 61) received 30 mg/m

Indexed as

Hematopoietic Stem Cell TransplantationTransplantation ConditioningAgedAntineoplastic Combined Chemotherapy ProtocolsArea Under CurveBusulfanCombined Modality TherapyDisease ManagementDrug MonitoringGraft SurvivalGraft vs Host DiseaseHumansLeukemia, Myeloid, AcuteMaleMiddle AgedMyelodysplastic SyndromesBusulfanfludarabineVidarabineArea under the curveBusulfanConditioningPharmacokineticsTransplant-related toxicity

Identifiers

PMID34523110
OpenAlexW3201206697

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.